You are viewing the site in preview mode

Skip to main content

Table 1 List of subjects enrolled in the study

From: TDP-43 seeding activity in the olfactory mucosa of patients with amyotrophic lateral sclerosis

Clinical Diagnosis

OM samples (number)

Age, mean (SD) (y)

Sex (M/F)

Age at onset, mean (SD) (y)

Disease duration, mean (SD) (m)

ALSFRS-R, mean (SD; range)

Progression rate, mean (SD)

Cognitive phenotype

(ALScn/ALSimp/FTD)

Onset region (number; spinal/bulbar)

Sporadic MND

65

62.9 (10.1)

48/17

61 (10.3)

28 (27.4)

39.9 (5.5;19–47)

1.0 (0.6)

34/21/10

44/21

 sALS

35

62.1 (9.9)

27/8

61 (10.3)

20 (24.7)

39.6 (6.3;19–47)

0.8 (0.8)

22/9/4

35/0

 bALS

18

63.8 (10.0)

11/7

61 (9.8)

28 (22.1)

40.6 (4.0;32–46)

0.36 (0.3)

9/6/3

0/18

 PLS

10

62.9 (10.1)

9/1

59 (10.4)

47 (27.4)

NA

NA

3/5/2

9/1

 FOSMN

2

70.0 (0)

1/1

64 (6.4)

78 (78.5)

NA

NA

0/1/1

0/2

Genetic MND

21

58.9 (10.1)

10/11

55 (10.7)

46 (34.1)

38.6 (5.5;18–46)

0.38 (0.4)

15/1/2 §

14/6

 C9orf72exp

6 (1 presymptomatic)

60.0 (9.8)

4/2

59 (10.2)

30 (26.4)

40.2 (5.9;37–44)

0.4 (0.7)

4/1/1

3/2

 TARDBP

4

53.8 (10.2)

1/3

50 (10.4)

38 (18.8)

40.5 (4.0;34–46)

0.25 (0.7)

4/0/0

3/1

 SQSTM1

3

70.0 (10.5)

1/2

66 (10.7)

51 (20.0)

39.3 (5.4;35–43)

0.29 (0.8)

0/0/1 §

2/1

 C9orf72exp + SQSTM1

1

57

1/0

57

22

18

1.36

1/0/0

1/0

 OPTN

1

58

1/0

53

59

NA

NA

1/0/0

1/0

 GLE1

1

65

0/1

64

7

39

1.29

1/0/0

0/1

 FUS

1

49

1/0

47

17

44

0.24

1/0/0

1/0

 SOD1

4

55 (5.1)

1/3

48 (4.8)

92 (28.3)

38.0 (4.0; 36–44)

0.11 (0.05)

3/0/0 §

4/0

Other neurodegenerative diseases

17

67.4 (9.0)

14/3

NA

NA

NA

NA

NA

NA

 MSA

6

63.3 (8.1)

4/2

NA

NA

NA

NA

NA

NA

 DLB

8

69.0 (8.7)

8/0

NA

NA

NA

NA

NA

NA

 AD

3

71.0 (11.8)

2/1

NA

NA

NA

NA

NA

NA

CTRLs

22

51.9 (16.8)

11/11

NA

NA

NA

NA

NA

NA

TOTAL

121

61.1 (12.3)

82/39

NA

NA

NA

NA

NA

NA

  1. Abbreviations: OM = olfactory mucosa; SD = standard deviation; y = years; M = male; F = female; m = months; ALS-FRS-R = ALS Functional Rating Scale Revised; ALScn: cognitively normal ALS; ALSimp = ALS with cognitive impairment (including ALSci [ALS with cognitive impairment], ALSbi [ALS with behavioral impairment], ALScbi [ALS with combined cognitive and behavioral impairment], ALSnex [ALS with nonexecutive dysfunction]); ALS-FTD: ALS with frontotemporal dementia; MND = motor neuron disease; sALS = spinal-onset amyotrophic lateral sclerosis; bALS = bulbar-onset amyotrophic lateral sclerosis; PLS = primary lateral sclerosis; FOSMN = facial onset sensory and motor neuronopathy; C9orf72exp = chromosome 9 open reading frame 72 expansion; TARDBP = TAR DNA-binding protein; SQSTM1 = sequestosome 1; OPTN = optineurin; GLE1 = GLE1 RNA export mediator; FUS = fused in sarcoma; SOD1 = superoxide dismutase type 1; MSA = multiple system atrophy; DLB = dementia with Lewy body; AD = Alzheimer's disease; CTRLs = controls; NA = not assessed
  2. § Neuropsychological data are not available for three patients (2 SQSTM1, and 1 SOD1)